Integral Molecular Reaches Antibody License Deal With AstraZeneca For Oncology Therapeutics

Integral Molecular said that it reached an exclusive worldwide antibody license agreement with AstraZeneca (AZN,AZN.L) to develop therapeutics for multiple cancers.

As per the terms of the deal, Integral Molecular will provide an exclusive license to AstraZeneca for a collection of monoclonal antibodies for use in oncology. AstraZeneca will be solely responsible for all research, development, and commercial activities.

The antibodies licensed by AstraZeneca were discovered and characterized using Integral Molecular's platforms designed to yield antibodies against structurally complex membrane proteins.

The MPS Antibody Discovery platform, Lipoparticles, Membrane Proteome Array, and Shotgun Mutagenesis Epitope Mapping technologies were used to generate diverse antibodies with exceptional specificity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection. Insurance company Prudential plc reported Wednesday a sharp drop in first-half pre-tax profit. On an after-tax basis, the company recorded a profit, compared to last year's hefty loss, due to the absence of prior year's loss from discontinued operations. Separately, Prudential announced its 2022 first interim dividend of 5.74 US cents per ordinary share, which will be paid on September 27.
Follow RTT